Colorectal Polyps

Adenomatous and serrated polyps follow distinct pathways toward colorectal cancer. This difference reflects separate patterns of genetic and cellular disruption rather than a single route of tumor development. Recognizing the pathway represented by a polyp helps clinicians interpret its potential significance after removal, because the lesion’s biological category contributes to histopathological assessment and subsequent follow-up planning.

The central biological problem is loss of normal control over epithelial cell proliferation. Genetic and cellular changes allow lining cells to multiply in an abnormal manner, creating a growth that may remain benign, become precancerous, or be malignant. This range explains why tissue evaluation matters even when a patient feels well: the specimen can clarify the lesion’s category.

Most colorectal polyps produce no symptoms, so symptom-based assessment can miss them. Their silent course is a major reason screening is important, particularly because some lesions can progress toward colorectal cancer over time. Detecting a polyp before symptoms develop creates an opportunity for colonoscopic removal and tissue evaluation, linking early identification with both prevention and diagnosis.

Colonoscopy, sigmoidoscopy, and stool-based tests offer several screening routes for detecting colorectal polyps. Because many lesions cause no symptoms, these approaches can identify abnormalities before symptom-driven evaluation. Together, they support earlier detection and can lead to colonoscopic removal and further evaluation when a polyp is found.

During colonoscopy, clinicians can perform polypectomy, meaning removal of a detected polyp. This procedure has two linked consequences: it can reduce the lesion’s opportunity to contribute to colorectal cancer, and it supplies tissue for histopathological evaluation. Thus, colonoscopy can function as both a detection and an intervention procedure.

Histopathological evaluation examines the removed tissue to determine how the polyp should be classified within the benign, precancerous, or malignant range. That result is clinically useful because it helps guide follow-up care rather than treating every lesion as biologically identical. Tissue analysis therefore connects the procedure to medical decision-making.